Viruses, Vol. 12, Pages 998: Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?
Viruses, Vol. 12, Pages 998: Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?
Viruses doi: 10.3390/v12090998
Authors:
Ganesh Selvaraj Duraisamy
Dattatry Bhosale
Ivana Lipenská
Ivana Huvarova
Daniel Růžek
Marc Windisch
Andrew D. Miller
The management of chronic hepatitis B virus (CHB) infection is an area of massive unmet clinical need worldwide. In spite of the development of powerful nucleoside/nucleotide analogue (NUC) drugs, and the widespread use of immune stimulators such as interferon-alpha (IFNα) or PEGylated interferon-alpha (PEG-IFNα), substantial improvements in CHB standards of care are still required. We believe that the future for CHB treatment now rests with advanced therapeutics, vaccination, and precision medicine, if all are to bring under control this most resilient of virus infections. In spite of a plethora of active drug treatments, anti-viral vaccinations and diagnostic techniques, the management of CHB infection remains unresolved. The reason for this is the very complexity of the virus replication cycle itself, giving rise to multiple potential targets for therapeutic intervention some of which remain very intractable indeed. Our review is focused on discussing the potential impact that advanced therapeutics, vaccinations and precision medicine could have on the future management of ...
Source: Viruses - Category: Virology Authors: Ganesh Selvaraj Duraisamy Dattatry Bhosale Ivana Lipensk á Ivana Huvarova Daniel R ůžek Marc Windisch Andrew D. Miller Tags: Review Source Type: research
More News: Genetics | Hepatitis | Hepatitis B | Hepatitis Vaccine | Nanotechnology | Vaccines | Virology